Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adcetris-Levact · 1 trial · 2 indications
To evaluate the tolerability and toxicity of Adcetris-Levact (BV-Be) association.
To evaluate the efficacy in terms of Response Rate after treatment completion of Adcetris-Levact (BV-Be) association.
| Arm | Type | Description |
|---|---|---|
| Adcetris-Levact (BV-Be) Association | EXPERIMENTAL | Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles |
| Name | Type | Description |
|---|---|---|
| Adcetris-Levact | DRUG | Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles. |
Inclusion Criteria: 1. Patients with advanced classical Hodgkin Lymphoma according to the World Health Organization classification. All Hasenclever IPS prognostic groups accepted 2. Stages IIB to IV B 3. Age 60-80 years included 4. Patient not previously treated 5. ECOG ≤ 2 6. Patient with adequate...
Adcetris-Levact is a combination therapy being studied for the treatment of Hodgkin lymphoma in older patients. It is currently in Phase 1 clinical development, with a completed trial evaluating its clinical efficacy and safety in patients aged 60 years and older.
Adcetris-Levact is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this combination therapy for Hodgkin lymphoma.
Adcetris-Levact is in Phase 1 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
Adcetris-Levact has one completed clinical trial registered as NCT02467946, titled "Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient." This Phase 1 study enrolled 60 participants in France and evaluated the combination's efficacy and safety.
Adcetris-Levact is a combination therapy that includes Adcetris and Levact as its components. It is studied as a combined treatment regimen for Hodgkin lymphoma, distinct from either drug used alone.